

REFERENCES

1. Kumar V, Abbas AK, Fausto N, editors. Acute and chronic inflammation. Robbins & Cotran Pathologic Basis of Disease 7th edition. Philadelphia: Elsevier Saunders, 2005: 48-85.
2. Katzung BG, Furst DE. Section 36. Nonsteroidal Anti-Inflammatory Drugs; Disease-Modifying Antirheumatic Drug; Nonopioid Analgesics; Drugs Used in Gout. In: Katzung BG, editors. Basic and Clinical Pharmacology. San Francisco: Lange Medical book/ MC Graw- Hill Companies, 1997: 578-602.
3. Salmon JA, Higgs GA. Prostaglandins and leukotrienes as inflammatory mediators. British Medical Bulletin 1987; 43(2): 285-296.
4. Morrow JD, Ramwell II LJ. Eicosanoids and platelet-activating factor. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 10th edition. New York: McGraw Hill, 2001: 669-680.
5. Bisgaard H. Role of leukotrienes in asthma pathophysiology. Pediatric Pulmonology 2000; 30: 166-176.
6. Bley KR, Hunter JC, Eglen RM, Smith JAM. The role of IP prostanoid receptor in inflammatory pain. Trends in Pharmacological Sciences 1998; 19: 141-147.

7. Abe M, Oka T, Hori T, Takahashi S. Prostanoids in the preoptic hypothalamus mediate systemic lipopolysaccharide-induced hyperalgesia in rats. *Brain Research* 2001; 916(1-2): 41-49.
8. Pang L, Knox AJ. Effect of interleukin-1 beta, tumor necrosis factor-alpha and interferon-gamma on the induction of cyclo-oxygenase-2 in cultured human airway smooth muscle cells. *British Journal of Pharmacology* 1997; 121(3): 579-587.
9. Furst DE, Hillson J. Aspirin and other nonsteroidal anti-inflammatory drugs. In: Koopman WJ, editor. *Arthritis and allied conditions*. 14th edition. Philadelphia: Lippincott Williams and Wilkins, 2001: 665-716.
10. Piper PJ. Formation and actions of leukotrienes. *Physiological Reviews* 1984; 64: 744-761.
11. Waller DG, Renwick AG, Hillier K. Non-steroidal anti-inflammation drugs. In: *Medical pharmacology and therapeutics*. 1st edition. Spain: Harcourt Publishers Ltd., 2001: 305-314.
12. Griswold DE, Marshall J, Webb EF, Godfrey R, Newton Jr J, Di Martino MJ, *et al*. SK&F 86002: A structure novel anti-inflammatory agent that inhibits lipoxxygenase and cyclooxygenase mediated metabolism of arachidonic acid. *Biochemical Pharmacology* 1987; 36(20): 3463-3470.
13. Bertolini A, Ottani A, Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. *Pharmacology Research* 2001; 44(6): 437-450.
14. Coleman R. Eicosanoid receptors. In: Dale MM, Foreman JC, Fan TD, editors. *Textbook of Immunology*. 3rd edition. Oxford Blackwell Scientific Publications, 1994: 143-154.

15. Benjamini E, Coico R, Sunshine G. Elements of innate and acquired immunity.
In: Immunology: A Short Course. 4th edition. New York: Wiley-Liss.
Inc., 2000: 17-39.
16. Robber II LJ, Morrow JD. Analgesic-antipyretic and anti-inflammatory agents
and drugs employed in the treatment of gout. In: Hardman JG, Limbird
LE, editors. Goodman & Gilman's the pharmacological basis of
therapeutics. 10th edition. New York: McGraw Hill Companies, 2001:
687-731.
17. Janeway CA, Travers P, Walport M, Capra JD. Host defense against infection.
In: Immunobiology: The immune system I health and disease. 4th
edition. New York: Garland Publishing, 1999: 363-415.
18. Chandrasoma P, Taylor CR. Chronic inflammation. In: Chandrasoma P,
Taylor CR, editors. Concise pathology. 2nd edition. East Norwalk:
Appleton & Lange, 1995: 69-77.
19. Kontogiorgis CA, Hadjipavlou-Litina DJ. Non steroidal anti-inflammatory and
anti-allergy agents. Current Medicinal Chemistry 2002; 9(1): 89-98.
20. Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-
lipoxygenase. A new avenue in anti-inflammatory therapy. Biochemical
Pharmacology 2001; 62(11): 1433-1438.
21. David EG, Armen H. Pharmacology of Eicosanoids. Principles of
Pharmacology: The Pathophysiologic Basis of Drug Therapy, 2nd edition
Lippincott Williams & Wilkins, 2008: 747-767.

22. Gould BE. Inflammation and healing. In: Pathophysiology for the Health Professions. 2nd edition. Philadelphia: WB Saunders Company, 2002: 12-33.
23. Davies NM, Saleh JY, Skjodt NM. Detection and prevention of NSAID-induced enteropathy. Journal of Pharmaceutical Sciences 2000; 3(1): 137-155.
24. Furst DE, Munster T. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics and drugs used in gout. In: Katzung BG, editor. Basic and clinical pharmacology. 8th edition. New York: McGraw-Hill, 2001: 596-623.
25. Rampasath VR, Shanthi P, and Sachdanandam P. Anti-inflammatory effect of *Semecarpus anacardium* Linn. Nut Extract in Acute and chronic Inflammatory Conditions. Biological & Pharmaceutical Bulletin 2004; 27: 2028-2031.
26. Kumara NKVMR. Identification of strategies to improve research on medicinal plants used in Sri Lanka In: WHO Symposium. University of Ruhuna, Galle, Sri Lanka, 2001.
27. Subcharoen P. Present status of traditional medicine in Thailand. Proceeding of the: International seminar on value and utilization of traditional medicine in health development. Queen Sirikit National Convention Center, Bangkok, 1995: 292-302.
28. World Health Organization. Guidelines for the appropriate use of herbal medicines Manila: WHO Publication 1988: 15.

29. Amresh G, Reddy GD, Rao ChV, Singh PN. Evaluation of anti-inflammatory activity of *Cissampelos pareira* root in rats. *Journal of Ethnopharmacology* 2007; 110: 526–531.
30. El-Sayed NH, El-Eaky W, Ibahim MT, Mabry TJ. Antiinflammatory and ulcerogenic activities of *Salvia Triloba* extracts. *Fitoterapia* 2006; 77: 333–335.
31. Panthong A, Kanjanapothi D, Taesotikul T, Wongcome T, Reutrakul V. Anti-inflammatory and antipyretic properties of *Celrodendrum patasites* S. Moore. *Journal of Ethnopharmacology* 2003; 85: 151–156.
32. Panthong A, Norkaew P, Kanjanapothi D, Taesotikul T, Anantachoke N, Reutrakul V. Anti-inflammatory, analgesic and antipyretic activities of the extract of gamboge from *Garcinia hanburyi* Hook f. *Journal of Ethnopharmacology* 2007; 111: 335–340.
33. เอี่ยมพร วิสมหมาย, ปณิธาน แก้วดวงเทียน. ไม้ป่าขึ้นต้นของไทย 1. กรุงเทพฯ: โรงพิมพ์ เอช เอ็น กรุ๊ป 2547.
34. Cooke T. The flora of the presidency of Bombay, vol. I. Calcutta: Botanical Survey of India, 1967: 76–7.
35. Stevens PF. A revision of the Old World species of *Calophyllum* (Guttiferae). *Journal Arnold Arboretum* 1980; 61: 117–699.
36. Valdir P, Nagem TJ, Oliveira FFD. Tetraoxygenated naturally occurring xanthenes. *Phytochemistry* 2000; 55: 683–710.
37. Chairungstrilere N, Furukawa K, Ohta T, Nozoe S. Histaminergic and serotonergic receptor blocking substances from the medicinal plant *Garcinia mangostana*. *Planta Medica* 1996; 62: 471–472.

38. Likhiwitayawuid K, Phadungcharoen T, Mahidol C, Ruchirawat S. 7-O-methylgarcinone E from *Garcinia cowa*. *Phytochemistry* 1997; 45: 1299–1301.
39. Duke JA. *Handbook of Medical Herbs*. Library of Congress, New York 1985.
40. Evan WC. *Trease and Evans Pharmacognosy*, 14th edition. Saunders Company Limited, Nottingham, 1996: 290.
41. Balasubramanian K, Rajagopalan K. Novel xanthones from *Garcinia mangostana*, structures of BR-xanthone-A and BR-xanthone-B. *Phytochemistry* 1988; 27: 1552–1554.
42. Fujio A, Hideki T, Toshiyuki T, Iinuma M. A xanthone from pericarps of *Garcinia mangostana*. *Phytochemistry* 1995; 39: 943-944.
43. Malathi R, Kabaleeswaran V, Rajan SS. Structure of mangostin. *Journal of Chemical Crystallography* 2000; 30: 203-205.
44. Chairungsrilerd N, Takeuchi K, Ohizumi Y, Nozoe S, Ohta T. Mangostanol, A prenyl xanthone from *Garcinia Mangostana*. *Phytochemistry* 1996; 43: 1099-1102.
45. Jinsart W, Ternai B, Buddhasukh D, Polya GM. Inhibition of wheat embryo calcium-dependent protein kinase and other kinases by mangostin and γ -mangostin. *Phytochemistry* 1992; 31: 3711–3713.
46. Iikubo K, Ishikawa Y, Ando N, Umezawa K, Nishiyama S. The first direct synthesis of α -mangostin, a potent inhibitor of the acidic sphingomyelinase. *Tetrahedron Letters*. 2002; 43: 291–293.

47. Iinuma M, Tosa H, Tanaka T, Asai F, Kobayashi Y, Shimano R, Miyauchi KI. Antibacterial activity of xanthenes from guttiferaeous plants against methicillin-resistant *Staphylococcus aureus*. Journal of Pharmacy and Pharmacology 1996; 48: 861–865.
48. Chairungsrilerd N, Furukawa KI, Tadano T, Kisara K, Ohizumi Y. Effect of γ -mangostin through the inhibition of 5-hydroxy-tryptamine 2_A receptors in 5-fluoro-a-methyltryptamine induced head- twitch responses of mice. British Journal of Pharmacology 1998; 123: 855–862.
49. Chairungsrilerd N, Furukawa KI, Ohta T, Nozoe S, Ohizumi Y. Pharmacological properties of α -mangostin, a novel histamine H_1 receptor antagonist. European Journal of Pharmacology 1996; 314: 351–356.
50. Chen S.X., Wan M., Loh B.N. Active constituents against HIV-1 protease from *Garcinia mangostana*. Planta Medica 1996; 62: 381–382.
51. Vlietinck AJ, Bruyne TD, Apers S, Pieters LA. Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. Planta Medica. 1998; 64: 97–109.
52. Chen LG, Yang LL, Wang CC. Anti-inflammatory activity of mangostins from *Garcinia mangostana*. Food and Chemical Toxicology. 2008; 46: 688–693.
53. Brattsand R, Thalen A, Roemple K, Kallstrom L, Gruvstad E. Influence of 16 ζ , 17 ζ -acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. Journal of Steroids Biochemistry 1982; 16(6): 779-786.

54. Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drug. *Proceeding of the Society for Experimental Biology and Medicine* 1962; 11: 544-547.
55. Di Martino MJ, Campbell GK, Wolff CE, Hanna N. The pharmacology of arachidonic acid-induced rat paw edema. *Agents Actions* 1987; 21(3-4): 303-305.
56. Swingle KF, Shideman FE. Phases of the inflammatory response to subcutaneous implantation of a cotton pellet and their modification by certain anti-inflammatory agents. *Journal of Pharmacology and Experimental Therapeutics* 1972; 183: 226-234.
57. Bessey OA, Lowry OH, Brock MJ. Method for the determination of alkaline phosphatase with five cubic millimeters of serum. *Journal of Biological Chemistry* 1946; 164: 321-329.
58. Collier HO, Dinneen LC, Johnson CA, Schneider C. The abdominal constriction response and its suppression by analgesic drugs in the mouse. *British Journal of Pharmacology* 1968; 32: 295-310.
59. Nakamura H, Shimoda A, Ishii K, Kadokawa T. Central and peripheral analgesic action of non-acidic non-steroidal anti-inflammatory drugs in mice and rats. *Archives Internationales de Pharmacodynamic et de Therapie* 1986; 282: 16-25.
60. D'Amour FE, Smith DL. A method for determining loss of pain sensation. *Journal of Pharmacology and Experimental Therapeutics* 1941; 72: 74-79.

61. Gray WD, Osterberg AC, Scute TJ. Measurement of the analgesic efficacy and potency of pentazocine by the D'Amour and Smith method. *Journal of Pharmacological and Experimental Therapeutics* 1970; 172: 154–162.
62. OECD guidelines for testing of chemicals. Organization of economic cooperation and development. 2001.
63. Ronald B, Mark L, Norman W. Nonsteroidal Anti-Inflammatory Drugs. *Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy*, 2nd edition Lippincott Williams & Wilkins, 2008: 955-1003.
64. Carlson RP, O'Neill-Davis L, Chang J, Lewis AJ. Modulation of mouse ear edema by cyclooxygenase and lipooxygenase inhibitors and other pharmacologic agents. *Agents Actions* 1985; 17(2): 197-204.
65. Di Rosa M. Biological properties of carrageenan. *Journal of Pharmacy and Pharmacology* 1972; 24 (2): 89–102.
66. Vinegar R, Schreiber W, Hugo R. Biphasic development of carrageenin edema in rats. *The Journal of Pharmacology and Experimental Therapeutics* 1969; 166(1): 96-103.
67. Spector WG. The granulomatous inflammatory exudate. *International Research in Experimental Pathology* 1969; 8: 1–55.
68. Bailey PJ, Sturm A, Lopez-Ramos B. A biochemical study of the cotton pellet granuloma in the rat. Effects of dexamethasone and indomethacin. *Biochemical Pharmacology* 1982; 31(7): 1213-1218.
69. Salmon JA, Higgs GA. Prostaglandins and leukotrienes as inflammatory mediators. *British medical bulletin* 1987; 43(2): 285-296.

70. Lsmail TS, GOpalakrishnan S, Begum VH, Elango V. Anti-inflammatory activity of *Salacia oblonga* Wall. And *Azima tetracantha* Lam. Journal of Ethnopharmacology 1997; 56(2): 145-152.
71. Raj PP. Pain mechanisms. In: Raj PP editor. Pain Medicine: A Comprehensive Review, 1st edition. Mosby-Year Book, Missouri, 1996: 12-23.
72. Burian M, Geisslinger G. Cox-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacology & Therapeutics 2005; 107(2): 139-154.
73. Gupta MM., Verma RK. Lipid constituents of *Cissus quadrangularis*. Phytochemistry 1991; 30 (3): 875-878.
74. Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neuroscience Research 2001; 41(4): 299-332.